The Amarin Corporation (NASDAQ:AMRN) Advisory Committee meeting is fast approaching. Ahead of the Briefing Documents release, we want to know what YOU think.
I believe the tone of the FDA briefing documents WILL be supportive of approval
83% (136 votes)
I believe the tone of the FDA briefing documents will NOT be supportive of approval
17% (28 votes)
Total votes: 163